Stealth BioTherapeutics Corp. (MITO)
Stock Price:
$1.43 USD
-0.04 (-2.72%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
71.20M |
| Revenue (ttm) |
21.09M |
| Net Income (ttm) |
-71.73M |
| Shares Out |
49.79M |
| EPS (ttm) |
-1.04 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$1.43 |
| Previous Close |
$1.47 |
| Change ($) |
-0.04 |
| Change (%) |
-2.72% |
| Day's Open |
1.48 |
| Day's Range |
1.41 - 1.47 |
| Day's Volume |
6,330 |
| 52-Week Range |
0.90 - 14.41 |
More Stats
| Market Cap |
71.20M |
| Enterprise Value |
36.67M |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
49.79M |
| Float |
n/a |
| EPS (basic) |
-2.28 |
| EPS (diluted) |
-1.04 |
| FCF / Share |
-1.54 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
97,916 |
| Short Ratio |
1.57 |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.38 |
| PB Ratio |
6.29 |
| Revenue |
21.09M |
| Operating Income |
-45.83M |
| Net Income |
-71.73M |
| Free Cash Flow |
-48.11M |
| Net Cash |
34.53M |
| Net Cash / Share |
0.69 |
| Gross Margin |
100.00% |
| Operating Margin |
-217.35% |
| Profit Margin |
-340.20% |
| FCF Margin |
-228.17% |
| ROA |
-54.61% |
| ROE |
-263.75% |
| ROIC |
-184.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
1 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$2.92*
(104.20% upside)
Low
1.75
Current: $1.43
High
5.00
Target: 2.92
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 21.09 | - | - | - |
| Gross Profit | 21.09 | - | - | - |
| Operating Income | -45.83 | -75.28 | -79.72 | -61.85 |
| Net Income | -71.73 | -96.71 | -82.91 | -61.05 |
| Shares Outstanding | 376 | 68.48 | 68.47 | 68.17 |
| Earnings Per Share | -2.28 | -16.92 | -14.52 | -10.80 |
| Operating Cash Flow | -47.98 | -72.08 | -69.84 | -54.02 |
| Capital Expenditures | -0.13 | -0.01 | -0.16 | -0.29 |
| Free Cash Flow | -48.11 | -72.09 | -70.00 | -54.31 |
| Cash & Equivalents | 50.77 | 10.86 | 4.12 | 9.71 |
| Total Debt | 16.24 | 122 | 64.05 | - |
| Net Cash / Debt | 34.53 | -111 | -59.93 | 9.71 |
| Assets | 52.74 | 15.52 | 7.15 | 13.32 |
| Liabilities | 35.48 | 191 | 87.06 | 11.78 |
| Book Value | 17.27 | -387 | -291 | -210 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Stealth BioTherapeutics Corp. |
| Country |
United States |
| Employees |
73 |
Stock Information
| Ticker Symbol |
MITO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MITO |
| IPO Date |
February 15, 2019 |
Description
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in George Town, the Cayman Islands.